Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

Lipid-Lowering Drugs

Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study

JAMA Cardiol.

Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, Ruzza A, Ma Y, Somaratne R, Raal FJ

doi: 10.1001/jamacardio.

RECOMMENDED

Lipid-Lowering Drugs

Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program

Atherosclerosis.

Farnier M, Hovingh GK, Langslet G, Dufour R, Baccara-Dinet MT, Din-Bell C, Manvelian G, Guyton JR

doi: 10.1016/j.atherosclerosis.

RECOMMENDED

Heart, Artery and Coronary DiseasesLipid-Lowering Drugs

Long-Term Evolocumab in Patients With Familial Hypercholesterolemia

★ 3 Recommended by Prof. Dr Isabella Sudano, Faculty Member

J Am Coll Cardiol.

Santos RD, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, López JAG, Bray S, Kurtz CE, Hamer AW, Raal FJ

doi: 10.1016/j.jacc.2019.12.020.

Lipid-Lowering Drugs

Pooled Safety Analysis of Evolocumab in Over 6000 Patients from Double-Blind and Open-label Extension Studies

Circulation

Toth PP, Descamps O, Genest J, Sattar N, Preiss D, Dent RE, Djedjos CS, Wu Y, Geller M, Uhart M, Somaratne R, Wasserman SM; PROFICIO Investigators

doi: 10.1161/CIRCULATIONAHA.

Heart, Artery and Coronary DiseasesLipid-Lowering Drugs

Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment.

Int J Cardiol.

Dufour R, Bergeron J, Gaudet D, Weiss R, Hovingh GK, Qing Z, Yang F, Andisik M, Torri A, Pordy R, Gipe DA

doi: 10.1016/j.ijcard.2016.11.046.

Cardiac Arrest or DeathCardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesHeart FailureMyocardial InfarctionThrombosis and Stroke

Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial

Lancet

Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, Ralston SH, Walters M, Robertson M, De Caterina R, Findlay E, Perez-Ruiz F, McMurray JJV, MacDonald TM, FAST Study Group.

doi: 10.1016/S0140-6736(20)32234-0

RECOMMENDED

Cardiovascular Risk and Diseases

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

★ 3 Recommended by Prof. Dr Isabella Sudano, Faculty Member

Lancet

EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).

doi: 10.1016/S0140-6736(21)01122-3

RECOMMENDED

Thrombosis and StrokeTherapy and Intervention

Long-term antithrombotic therapy and risk of intracranial haemorrhage from cerebral cavernous malformations: a population-based cohort study, systematic review, and meta-analysis

Lancet Neurol.

Zuurbier SM, Hickman CR, Tolias CS, Rinkel LA, Leyrer R, Flemming KD, Bervini D, Lanzino G, Wityk RJ, Schneble HM, Sure U, Al-Shahi Salman R, Scottish Audit of Intracranial Vascular Malformations Steering Committee.

doi: 10.1016/S1474-4422(19)30231-5.

Therapy and Intervention

Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study)

Eur Heart J.

Giacoppo D, Alfonso F, Xu B, Claessen BEPM, Adriaenssens T, Jensen C, Pérez-Vizcayno MJ, Kang DY, Degenhardt R, Pleva L, Baan J, Cuesta J, Park DW, Schunkert H, Colleran R, Kukla P, Jiménez-Quevedo P, Unverdorben M, Gao R, Naber CK, Park SJ, Henriques JPS, Kastrati A, Byrne RA

doi: 10.1093/eurheartj/ehz594.

Related content

Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study

Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program

Long-Term Evolocumab in Patients With Familial Hypercholesterolemia

Pooled Safety Analysis of Evolocumab in Over 6000 Patients from Double-Blind and Open-label Extension Studies

Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment.

Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Long-term antithrombotic therapy and risk of intracranial haemorrhage from cerebral cavernous malformations: a population-based cohort study, systematic review, and meta-analysis

Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study)